RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolioCollaboration combines Moderna’s expertise in mRNA technology for ...
Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
mRNA-3927 is an investigational novel mRNA-based therapeutic agent that is composed of two mRNAs encoding for normal human ...
Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...
If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.
CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for ...
Zacks Investment Research on MSN
Moderna (MRNA) increases despite market slip: Here's what you need to know
In the latest trading session, Moderna (MRNA) closed at $43.00, marking a +2.8% move from the previous day. The stock's change was more than the S&P 500's daily loss of 2.06%. On the other hand, the ...
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic ...
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for ...
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David ...
Up to $54.3 million CEPI investment aims to help advance Moderna’s H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results